BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16843676)

  • 1. Multitargeted therapy: can promiscuity be praised in an era of political correctness?
    Jimeno A; Hidalgo M
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):150-8. PubMed ID: 16843676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel targets for cancer chemotherapy].
    Inoue S
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):191-201. PubMed ID: 8611047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of cellular differentiation and cell fate for cancer therapy.
    Moutouh-de Parseval LA; Chan KW
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1268-73. PubMed ID: 15648947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy: for kids, too.
    Corey SJ
    Pediatr Blood Cancer; 2005 Oct; 45(5):623-34. PubMed ID: 15704219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis.
    Hu X; Xuan Y
    Cancer Lett; 2008 Feb; 259(2):127-37. PubMed ID: 18082322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New frontiers in cancer treatment].
    Tortora G; Daniele G
    Recenti Prog Med; 2006 Dec; 97(12):781-6. PubMed ID: 17252737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Target selectivity of anticancer drugs].
    Fattoruso SI; Di Lauro L; Conti F; Amodio A; Lopez M
    Clin Ter; 2008; 159(3):189-206. PubMed ID: 18594750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical modeling of combination treatments: fantasy or requirement?
    Decker S; Sausville EA
    Ann N Y Acad Sci; 2005 Nov; 1059():61-9. PubMed ID: 16382044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
    Weinstein IB; Joe AK
    Nat Clin Pract Oncol; 2006 Aug; 3(8):448-57. PubMed ID: 16894390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biological framework: translational research from bench to clinic.
    Yarden Y
    Oncologist; 2010; 15 Suppl 5():1-7. PubMed ID: 21138950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
    de Jonge MJ; Verweij J
    Eur J Cancer; 2006 Jul; 42(10):1351-6. PubMed ID: 16740386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for optimizing combinations of molecularly targeted anticancer agents.
    Dancey JE; Chen HX
    Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents.
    Garattini E; Gianni' M; Terao M
    Vitam Horm; 2007; 75():301-54. PubMed ID: 17368321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular insight in cancer treatment and prevention.
    Balducci L
    Int J Biochem Cell Biol; 2007; 39(7-8):1329-36. PubMed ID: 17531523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.